Core Viewpoint - The company, Chuaning Bio (301301.SZ), confirmed that its antibiotic intermediates can play a supportive role in the treatment of bacterial complications arising from influenza, such as bacterial pneumonia [2] Company Overview - Chuaning Bio specializes in the production of antibiotic intermediates, with key products including thiocyanate erythromycin, cephalosporin intermediates, and penicillin intermediates [2] - The company's products are utilized in the synthesis of antibacterial drugs, indicating its role in the pharmaceutical supply chain [2] Industry Context - In cases where influenza patients develop bacterial complications, clinical doctors may prescribe antibiotics as part of the treatment plan, highlighting the relevance of the company's products in clinical settings [2]